• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors.长期前列腺癌幸存者中患者报告与医生报告的晚期放射毒性比较
Cancers (Basel). 2022 Mar 25;14(7):1670. doi: 10.3390/cancers14071670.
2
Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy.图像引导放疗时代的晚期放射毒性遗传标志物:较低的毒性发生率降低了接受盆腔放疗患者 γ-H2AX 焦点衰减比的预测价值。
Radiat Oncol. 2024 Sep 2;19(1):116. doi: 10.1186/s13014-024-02501-x.
3
Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity Than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.伽马-H2AX 焦点衰减比作为前列腺癌患者前瞻性队列中比剂量-体积参数更强的晚期放射毒性预测因子。
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):212-221. doi: 10.1016/j.ijrobp.2021.08.020. Epub 2021 Aug 20.
4
Prostate Cancer Patients with Late Radiation Toxicity Exhibit Reduced Expression of Genes Involved in DNA Double-Strand Break Repair and Homologous Recombination.晚期放射性毒性的前列腺癌患者表现出参与 DNA 双链断裂修复和同源重组的基因表达降低。
Cancer Res. 2017 Mar 15;77(6):1485-1491. doi: 10.1158/0008-5472.CAN-16-1966. Epub 2017 Jan 20.
5
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.超分割与常规分割放疗治疗前列腺癌的比较:HYPO-RT-PC 随机、非劣效、III 期临床试验的 5 年结果。
Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.
6
Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.前列腺癌根治术后调强放疗的患者报告结局和晚期毒性。
Eur Urol. 2019 Nov;76(5):686-692. doi: 10.1016/j.eururo.2019.05.011. Epub 2019 May 19.
7
Reduced activity of double-strand break repair genes in prostate cancer patients with late normal tissue radiation toxicity.前列腺癌患者晚期正常组织放射性毒性与双链断裂修复基因活性降低有关。
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):664-70. doi: 10.1016/j.ijrobp.2013.11.219. Epub 2014 Jan 8.
8
Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.单次大剂量率近距离放疗加量与低分割外照射放疗治疗中危前列腺癌后的长期毒性及健康相关生活质量
Clin Oncol (R Coll Radiol). 2017 Jul;29(7):412-420. doi: 10.1016/j.clon.2017.01.042. Epub 2017 Feb 9.
9
The Cambridge Breast Intensity-modulated Radiotherapy Trial: Comparison of Clinician- versus Patient-reported Outcomes.剑桥乳腺调强放射治疗试验:临床医生报告与患者报告结果的比较
Clin Oncol (R Coll Radiol). 2016 Jun;28(6):354-64. doi: 10.1016/j.clon.2016.02.011. Epub 2016 Mar 24.
10
Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up.PROMs 是否足以记录接受放疗的乳腺癌患者的晚期结局?通过 10 年随访后的门诊随访,比较患者和临床医生报告的结局。
Radiother Oncol. 2018 Jan;126(1):163-169. doi: 10.1016/j.radonc.2017.08.004. Epub 2017 Aug 24.

引用本文的文献

1
Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.迈向盆腔癌的个性化放疗:晚期放射毒性的患者相关风险因素
Curr Oncol. 2025 Jan 17;32(1):47. doi: 10.3390/curroncol32010047.
2
Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy.图像引导放疗时代的晚期放射毒性遗传标志物:较低的毒性发生率降低了接受盆腔放疗患者 γ-H2AX 焦点衰减比的预测价值。
Radiat Oncol. 2024 Sep 2;19(1):116. doi: 10.1186/s13014-024-02501-x.
3
Evaluation of Relationship between Intrinsic Radiosensitivity (Survival Fraction at 2 Gy) and Gamma-H2AX Test and Apoptosis of Lymphocytes in Breast Cancer Patients.乳腺癌患者内在放射敏感性(2 Gy时的存活分数)与γ-H2AX检测及淋巴细胞凋亡之间关系的评估
J Med Signals Sens. 2024 Jul 10;14:17. doi: 10.4103/jmss.jmss_40_23. eCollection 2024.
4
A pooled patient-reported outcomes analysis of moderately hypofractionated proton beam therapy and photon-based intensity modulated radiation therapy for low- or intermediate-risk prostate cancer.中低危前列腺癌质子束调强放疗与光子调强放疗的患者报告结局的汇总分析。
Prostate. 2024 Mar;84(4):395-402. doi: 10.1002/pros.24660. Epub 2023 Dec 18.
5
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study.急性与晚期泌尿生殖系统及胃肠道毒性之间的关联:PACE B研究分析
Cancers (Basel). 2023 Feb 17;15(4):1288. doi: 10.3390/cancers15041288.
6
Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose.利用计划剂量和实际给予剂量对前列腺放疗后晚期直肠和泌尿毒性进行预测建模。
Front Oncol. 2022 Dec 16;12:1084311. doi: 10.3389/fonc.2022.1084311. eCollection 2022.

本文引用的文献

1
A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients.一项高危前列腺癌患者全盆腔放疗后急性和晚期医生评估及患者报告发病率的 I/II 期研究。
Acta Oncol. 2022 Feb;61(2):179-184. doi: 10.1080/0284186X.2021.1979246. Epub 2021 Sep 20.
2
Gamma-H2AX Foci Decay Ratio as a Stronger Predictive Factor of Late Radiation Toxicity Than Dose-Volume Parameters in a Prospective Cohort of Prostate Cancer Patients.伽马-H2AX 焦点衰减比作为前列腺癌患者前瞻性队列中比剂量-体积参数更强的晚期放射毒性预测因子。
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):212-221. doi: 10.1016/j.ijrobp.2021.08.020. Epub 2021 Aug 20.
3
Patient reported toxicity and quality of life after hypofractionated high-dose intensity-modulated radiotherapy for intermediate- and high risk prostate cancer.患者报告的中高危前列腺癌大分割高剂量调强放疗后的毒性反应及生活质量
Clin Transl Radiat Oncol. 2021 May 21;29:40-46. doi: 10.1016/j.ctro.2021.05.005. eCollection 2021 Jul.
4
Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.高危前列腺癌患者行前列腺区或全盆腔放疗的晚期毒性和生活质量(POP-RT):一项随机试验。
Radiother Oncol. 2020 Apr;145:71-80. doi: 10.1016/j.radonc.2019.12.006. Epub 2020 Jan 7.
5
Reporting of Late Morbidity After Radiation Therapy in Large Prospective Studies: A Descriptive Review of the Current Status.放疗后晚期并发症的报告:对当前现状的描述性综述。
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):957-967. doi: 10.1016/j.ijrobp.2019.08.040. Epub 2019 Aug 27.
6
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.超分割与常规分割放疗治疗前列腺癌的比较:HYPO-RT-PC 随机、非劣效、III 期临床试验的 5 年结果。
Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.
7
Implementation of Patient-Reported Outcomes in Routine Medical Care.患者报告结局在常规医疗中的应用
Am Soc Clin Oncol Educ Book. 2018 May 23;38:122-134. doi: 10.1200/EDBK_200383.
8
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.标准全前列腺放疗联合或不联合病灶加量放疗治疗前列腺癌:FLAME 随机对照试验中的毒性反应。
Radiother Oncol. 2018 Apr;127(1):74-80. doi: 10.1016/j.radonc.2017.12.022. Epub 2018 Jan 11.
9
Are PROMs sufficient to record late outcome of breast cancer patients treated with radiotherapy? A comparison between patient and clinician reported outcome through an outpatient clinic after 10years of follow up.PROMs 是否足以记录接受放疗的乳腺癌患者的晚期结局?通过 10 年随访后的门诊随访,比较患者和临床医生报告的结局。
Radiother Oncol. 2018 Jan;126(1):163-169. doi: 10.1016/j.radonc.2017.08.004. Epub 2017 Aug 24.
10
Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.根治性放射治疗前列腺癌治疗相关的急性和晚期不良反应:随机对照试验中临床医生和患者毒性报告的系统评价。
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):495-510. doi: 10.1016/j.ijrobp.2016.11.008. Epub 2016 Nov 18.

长期前列腺癌幸存者中患者报告与医生报告的晚期放射毒性比较

A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors.

作者信息

Nuijens Anna C, Oei Arlene L, Bouhuijs Anne, Franken Nicolaas A P, Rasch Coen R N, Stalpers Lukas J A

机构信息

Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Meibergdreef, 1105 AZ Amsterdam, The Netherlands.

Center for Experimental and Molecular Medicine (CEMM), Laboratory for Experimental Oncology and Radiobiology (LEXOR), Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Meibergdreef, 1105 AZ Amsterdam, The Netherlands.

出版信息

Cancers (Basel). 2022 Mar 25;14(7):1670. doi: 10.3390/cancers14071670.

DOI:10.3390/cancers14071670
PMID:35406443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8996858/
Abstract

Patient-reported outcome measures (PROMs) are advocated for the monitoring of toxicity after radiotherapy. However, studies comparing physician- and patient-reported toxicity show low concordance. In this study, we compared physician- and patient-reported toxicity in long-term prostate cancer survivors after radiotherapy, and we determined the correlation with a presumable risk factor for late toxicity: γ-H2AX foci decay ratio (FDR). Patients formerly included in a prospective study were invited to participate in this new study, comprising one questionnaire and one call with a trial physician assistant. Concordance was calculated for seven symptoms. Gamma-H2AX FDRs were determined in ex vivo irradiated lymphocytes in a previous analysis. Associations between FDR and long-term prevalence of toxicity were assessed using univariable logistic regression analyses. The 101 participants had a median follow-up period of 9 years. Outcomes were discordant in 71% of symptomatic patients; in 21%, the physician-assessed toxicity (using CTCAE) was higher, and, in 50%, the patients reported higher toxicity. We did not find a correlation between presence of toxicity at long-term follow-up and FDR. In conclusion, patients assigned greater severity to symptoms than the trial physician assistant did. Consideration of both perspectives may be warranted to provide the best care.

摘要

患者报告结局指标(PROMs)被提倡用于监测放疗后的毒性反应。然而,比较医生报告和患者报告的毒性反应的研究显示一致性较低。在本研究中,我们比较了放疗后长期前列腺癌幸存者中医生报告和患者报告的毒性反应,并确定了与晚期毒性反应的一个可能风险因素:γ-H2AX焦点衰减率(FDR)之间的相关性。以前纳入一项前瞻性研究的患者被邀请参加这项新研究,包括一份问卷和与试验医生助理的一次电话沟通。计算了七种症状的一致性。在之前的一项分析中,在体外照射的淋巴细胞中测定了γ-H2AX FDRs。使用单变量逻辑回归分析评估FDR与长期毒性反应患病率之间的关联。101名参与者的中位随访期为9年。在71%有症状的患者中,结果不一致;在21%的患者中,医生评估的毒性反应(使用CTCAE)更高,而在50%的患者中,患者报告的毒性反应更高。我们没有发现长期随访时毒性反应的存在与FDR之间存在相关性。总之,患者认为症状的严重程度高于试验医生助理。可能有必要考虑双方的观点以提供最佳护理。